To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.
Nebivolol treatment exhibited remarkable protective effects on bleomycin-mediated IPF in rats via suppressing TLR4/IL-1β/MMP-2 and TGF-β/HSP47 signaling pathways. This study might provide an innovative therapeutic approach to prevent the devastating lung scarring associated with IPF.
11 days ago
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SERPINH1 (Serpin family H member 1) • MMP2 (Matrix metallopeptidase 2) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
This study showed that tumor-bearing status elicits proinflammatory activation in endothelial cells and inflammatory cell infiltration into the lungs that aggravates DILD caused by BLM.
The combination of PFD, MET, and BM-MSCs offered superior therapeutic efficacy in treating BLM-induced pulmonary fibrosis compared to individual treatments. This multimodal approach effectively targets oxidative stress, inflammation, apoptosis, and fibrosis, suggesting strong potential for future clinical application.
P=N/A, N=10, Active, not recruiting, University Medical Centre Ljubljana | Terminated --> Active, not recruiting | Phase classification: P1 --> PN/A | Trial completion date: Mar 2021 --> May 2026
25 days ago
Enrollment closed • Phase classification • Trial completion date
Extragonadal penile localization of endodermal sinus tumor is rare but has a favorable prognosis when treated with conservative management and chemotherapy. aFP is a useful marker for both diagnosis and follow-up.
Importantly, the therapeutic effects of HA-Wm were abolished in Fpr2-deficient mice, confirming an FPR2-dependent mechanism of action. Collectively, these results demonstrate that topical treatment of HA-Wm alleviates skin fibrosis and inflammation via an FPR2-dependent pathway, representing a promising noninvasive therapeutic avenue for fibrotic skin disorders such as systemic sclerosis.
Using DDX41 knockout (KO) cells, we found that these cells were sensitive to bleomycin, camptothecin, and UV...Moreover, increased and prolonged RPA and reduced RAD51 foci were found in DDX41 KO and DDX41-R525H expressing cells, indicating a defect in the transition from end resection to RAD51 filament assembly. Overall, our results suggest that DDX41 utilizes its unwinding activity to resolve R-loops, which may play a key role in HR-based repair, and dysregulation of this pathway may lead to MDS/AML.